Clinical Trials for Relapsed/Refractory Multiple Myeloma

A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma

NCT ID: NCT05160584

This clinical trial is studying how well current treatments for multiple myeloma work in everyday medical practice. Specifically, it focuses on patients who have already received treatment for thei...

Long-Term Follow-up Study

NCT ID: NCT05332054

A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

NCT ID: NCT05704049

This clinical trial is looking at a new treatment for adults with relapsed or refractory multiple myeloma (RRMM), which means their cancer has returned or has not responded to previous treatments. ...

A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma

NCT ID: NCT06669247

This clinical trial is investigating the safety and effectiveness of two experimental drugs, REGN7945 and linvoseltamab, for adults with relapsed or refractory multiple myeloma, a type of blood can...

A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients

NCT ID: NCT06508983

This clinical trial is studying a new treatment approach for patients with relapsed or refractory multiple myeloma, a type of blood cancer that has returned or did not respond to previous treatment...

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

NCT ID: NCT04973605

This clinical trial is studying a new treatment called BGB-11417 for patients with relapsed or refractory multiple myeloma, which is a type of blood cancer. The trial has two parts: the first part ...

A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

NCT ID: NCT05219721

This clinical trial is testing a new treatment called CAR-GPRC5D for patients with relapsed or refractory multiple myeloma and plasma cell leukemia. This means the study is looking at how well this...

Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)

NCT ID: NCT05862012

This clinical trial is testing a new treatment called ISB 2001 for patients with relapsed or refractory multiple myeloma, which means their cancer has returned or not responded to previous treatmen...

A Phase I/II Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma

NCT ID: NCT06049290

This clinical trial is studying a new treatment called LBL-034 for patients with relapsed or refractory multiple myeloma, which means their cancer has come back or hasn’t responded to other treatme...

A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma

NCT ID: NCT05874193

This clinical trial is studying a medication called belantamab mafodotin, along with a steroid called dexamethasone, to see if it can be safely and effectively given to patients with relapsed or re...

A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

NCT ID: NCT05759793

This clinical trial is investigating a new treatment called CAR-GPRC5D for patients with relapsed or refractory multiple myeloma (a type of blood cancer) or plasma cell leukemia. The goal is to see...

CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

NCT ID: NCT05722418

This clinical trial is studying a new treatment called CB-011 for patients with relapsed or refractory multiple myeloma, which means their cancer has returned or has not responded to previous thera...

LCAR-M61SQ in Treatment of Relapsed/Refractory Multiple Myeloma

NCT ID: NCT06888752

This clinical trial is studying a new treatment called LCAR-M61SQ for people with relapsed or refractory multiple myeloma, which means their cancer has come back or hasn’t responded to previous tre...

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma

NCT ID: NCT05259839

This clinical trial is studying the safety and effectiveness of a new drug called ABBV-383 when given together with other treatments for adults with relapsed or refractory multiple myeloma, a type ...

An Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Patients With Relapsed/Refractory Multiple Myeloma

NCT ID: NCT06668792

This clinical trial is studying a new treatment called BCD-248 for patients with relapsed or refractory multiple myeloma, a type of blood cancer that has come back or hasn’t responded to other trea...

A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell Leukemia

NCT ID: NCT06730256

This clinical trial is studying a new treatment called CT0596, which is a type of CAR-T cell therapy, for patients with relapsed or refractory multiple myeloma and plasma cell leukemia. This means ...

a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia

NCT ID: NCT06718270

This clinical trial is studying a new treatment called CT0596 for patients with relapsed or refractory multiple myeloma and plasma cell leukemia. This means the treatment is aimed at patients whose...

A Real-World Observational Study: Zevorcabtagene Autoleucel Injection in Patients with Relapsed/Refractory Multiple Myeloma

NCT ID: NCT06659770

This clinical trial is looking at a new treatment called zevorcabtagene autoleucel (often shortened to zevor-cel) for people with relapsed or refractory multiple myeloma, which means their cancer h...

An Exploratory Study of RD140 Injection in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

NCT ID: NCT06655519

This clinical trial is exploring the safety and effectiveness of a new treatment called RD140 injection for patients with relapsed or refractory multiple myeloma and plasma cell leukemia. These con...

Cevostamab Following CAR T Cell Therapy for RRMM

NCT ID: NCT05801939

This clinical trial, called "Cevostamab Following CAR T Cell Therapy for Relapsed/Refractory Multiple Myeloma," is studying the effects of a treatment called cevostamab given to patients who have a...